Ineffectiveness of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer

Annals of Surgery

Volumn 258, Issue 1, 2013, Pages 66-76

  Piessen, Guillaume ^a,b,c   Petyt, Grégory ^a,b   Duhamel, Alain ^a,b   Mirabel, Xavier ^b,d   Huglo, Damien ^a,b   Mariette, Christophe ^a,b,c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

^c JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^d CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

Chemoradiation; Esophageal cancer; Positron emission tomography; Surgery; Survival

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADENOCARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CAUSE OF DEATH; CERVICAL LYMPH NODE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DRUG UPTAKE; ESOPHAGUS CANCER; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RESPIRATORY DISTRESS SYNDROME; SQUAMOUS CELL CARCINOMA; SURGICAL MORTALITY; TREATMENT RESPONSE; ADJUVANT THERAPY; CANCER STAGING; CHEMORADIOTHERAPY; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SCINTISCANNING; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CISPLATIN; DATA INTERPRETATION, STATISTICAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84879105617     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31828676c4     Document Type: Article

References (42)

1. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007;8:545-553.
2. Mariette C, Piessen G, Lamblin A, et al. Impact of preoperative radiochemotherapy on postoperative course and survival in patients with locally advanced squamous cell oesophageal carcinoma. Br J Surg. 2006;93:1077-1083.
3. Bedenne L, Michel P, Bouch́e O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160-1168.
4. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310-2317.
5. Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004;78:1152-1160.
6. Sarkaria IS, Rizk NP, Bains MS, et al. Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg. 2009;249:764-767.
7. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680-2686.
8. Rebollo Aguirre AC, Ramos-Font C, Villegas Portero R, et al. 18F-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer: systematic review of the literature. Ann Surg. 2009;250:247-254.
9. Vallb̈ohmer D, Ḧolscher AH, Dietlein M, et al. [18F]-Fluorodeoxyglucosepositron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg. 2009;250:888-894.
10. Monjazeb AM, Riedlinger G, Aklilu M, et al. Outcomes of patients with esophageal cancer staged with [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol. 2010;28:4714-4721.
11. Van Heijl M, Omloo JM, Van Berge Henegouwen MI, et al. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg. 2011;253:56-63.
12. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797-805.
13. Levine EA, Farmer MR, Clark P, et al. Predictive value of 18-fluoro-deoxyglucosepositron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg. 2006;243:472-478.
14. Brink I, Hentschel M, Bley TA, et al. Effects of neoadjuvant radiochemotherapy on 18F-FDG-PET in esophageal carcinoma. Eur J Surg Oncol. 2004;30:544-550.
15. Cerfolio RJ, Bryant AS, Ohja B, et al. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg. 2005;129:1232-1241.
16. Song SY, Kim JH, Ryu JS, et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys. 2005;63:1053-1059.
17. Wong R, Walker-Dilks C, Raifu A. Evidence-based guideline recommendations on the use of positron emission tomography imaging in oesophageal cancer [published online ahead of print September 29, 2011]. Clin Oncol (R Coll Radiol). Available at: http://www.ncbi.nlm.nih.gov/pubmed/21962904. Accessed January 8, 2012.
18. The World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; Offset Publication No. 48, 1979.
19. Mariette C, Piessen G, Briez N, et al. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008;247:365-371.
20. Sobon LH, Wittekind C, eds. UICC TNM Classification of Malignant Tumors. 6th ed. New York, NY: Wiley; 2002.
21. Schneider PM, Baldus SE, Metzger R, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242:684-692.
22. Zepp R. Rocpower. SAS [Cleveland Clinic, Department of quantitative health science Web site]. Available at: http://www.bio.ri.ccf.org/doc/ rocpowerhelp. txt. Accessed March 30, 2012.
23. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
24. Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol. 2002;13:361-368.
25. Van Westreenen HL, Heeren PA, Van Dullemen HM, et al. Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations. J Gastrointest Surg. 2005;9:54-61.
26. Kneist W, Schreckenberger M, Bartenstein P, et al. Prospective evaluation of positron emission tomography in the preoperative staging of esophageal carcinoma. Arch Surg. 2004;139:1043-1049.
27. Van Westreenen HL, Westerterp M, Sloof GW, et al. Limited additional value of positron emission tomography in staging oesophageal cancer. Br J Surg. 2007;94:1515-1520.
28. Gillham CM, Lucey JA, Keogan M, et al. (18) FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer. 2006;95:1174-1179.
29. Westerterp M, Omloo JM, Sloof GW, et al. Monitoring of response to preoperative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET. Int J Hyperthermia. 2006;22:149-160.
30. Wieder HA, Brucher BL, Zimmermann F, et al. Time course of tumormetabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004;22:900-908.
31. Westerterp M, Van Westreenen HL, Reitsma JB, et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review. Radiology. 2005;236:841-851.
32. Rizk NP, Tang L, Adusumilli PS, et al. Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol. 2009;4:875-879.
33. Konski AA, Cheng JD, Goldberg M, et al. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2007;69:358-363.
34. Javeri H, Xiao L, Rohren E, et al. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009;115:5184-5192.
35. Roedl JB, Colen RR, Holalkere NS, et al. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation. Radiother Oncol. 2008;89:278-286.
36. McLoughlin JM, Melis M, Siegel EM, et al. Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer? J Am Coll Surg. 2008;206:879-886.
37. Schmidt M, Bollschweiler E, Dietlein M, et al. Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy. Eur J Nucl Med Mol Imaging. 2009;36:735-744.
38. Smithers BM, Couper GC, Thomas JM, et al. Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus. Dis Esophagus. 2008;21:151-158.
39. Mariette C, Finzi L, Fabre S, et al. Factors predictive of complete resection of operable esophageal cancer: a prospective study. Ann Thorac Surg. 2003;75:1720-1726.
40. Mariette C, Piessen G, Briez N, et al. Oesophagogastric junction adenocarcinoma: which therapeutic approach? Lancet Oncol. 2011;12:296-305.
41. Bouvier AM, Binquet C, Gagnaire A, et al. Management and prognosis of esophageal cancers: has progress been made? Eur J Cancer. 2006;42:228-233.
42. Bollschweiler E, Metzger R, Drebber U, et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol. 2009;20:231-238.